What is Biocytogen Pharmaceuticals (Beijing) Co Gross Margin %?
Biocytogen Pharmaceuticals (Beijing) CoFRA:I54 78 Gross Margin % is 77.01% as of Dec. 2025, which is 7% above its 10-year median of 71.99. GuruFocus rates FRA:I54 with a GF Score™ of 78/100 and a GF Value™ of €3.28 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 733 Biotechnology companies, Biocytogen Pharmaceuticals (Beijing) Co ranks better than 67.12% on this metric.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Biocytogen Pharmaceuticals (Beijing) Co had a gross margin of 77.01% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Biocytogen Pharmaceuticals (Beijing) Co Gross Margin % Related Terms
Biocytogen Pharmaceuticals (Beijing) Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co Gross Margin % Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
FRA:I54 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co Gross Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a Gross Margin % of 77.01% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. This is near median its historical median of 71.99. Over the past decade, Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin % has ranged from 65.86 to 77.67. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #241 out of 733 companies in the Biotechnology industry, placing it in the top 32.9%.
Is Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin % too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Gross Margin % of 77.01% is near median its 10-year median of 71.99. Over the past 10 years, this metric has ranged from a low of 65.86 to a high of 77.67. The Biotechnology industry median Gross Margin % is 60.90. Biocytogen Pharmaceuticals (Beijing) Co's value of 77.01% is 26.5% above this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #241 out of 733 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #241 out of 733 companies for Gross Margin %. This puts Biocytogen Pharmaceuticals (Beijing) Co in the upper half of its industry. The industry median Gross Margin % is 60.90. Biocytogen Pharmaceuticals (Beijing) Co's value of 77.01% is 26.5% above this benchmark. Historically, Biocytogen Pharmaceuticals (Beijing) Co's own Gross Margin % has ranged from 65.86 to 77.67 over the past decade. While the company's 10-year median is 71.99 vs. the industry median of 60.90, Biocytogen Pharmaceuticals (Beijing) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current Gross Margin % of 77.01% is 26.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current Gross Margin % is 77.01%, which is near median its own 10-year median of 71.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.28, compared to a current price of €5.15 — trading 57% above its estimated fair value. The current Gross Margin % is 77.01%, which is near median its 10-year median of 71.99 and 26.5% above the Biotechnology industry median of 60.90. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current Gross Margin % is 77.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of €5.15 is trading 57% above its estimated GF Value™ of €3.28.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for FRA:I54:
Gross Margin %: 77.01% (near median its 10-year median of 71.99)
GF Value™: €3.28 vs. price of €5.15 (57% above fair value)
Industry Position: 26.5% above the Biotechnology median (#241 of 733)
No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
78GF Score
Get the complete analysis for FRA:I54
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I54 has been successfully added to your 
